Department of Epidemiology, Geisel School of Medicine at Dartmouth, Lebanon, NH 03755, USA.
Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02215, USA.
Epigenomics. 2024;16(11-12):799-807. doi: 10.1080/17501911.2024.2343274. Epub 2024 May 17.
This study addresses the challenge of predicting the response of head and neck squamous cell carcinoma (HNSCC) patients to immunotherapy. Using DNA methylation cytometry, we analyzed the immune profiles of six HNSCC patients who showed a positive response to immunotherapy over a year without disease progression. There was an initial increase in CD8 T memory cells and natural killer cells during the first four cycles of immunotherapy, which then returned to baseline levels after a year. Baseline CD8 T cell levels were lower in HNSCC immunotherapy responders but became similar to those in healthy subjects after immunotherapy. These findings suggest that monitoring fluctuations in immune profiles could potentially identify biomarkers for immunotherapy response in HNSCC patients.
本研究旨在解决预测头颈部鳞状细胞癌（HNSCC）患者对免疫疗法反应的挑战。我们使用 DNA 甲基化细胞仪分析了 6 名 HNSCC 患者的免疫特征，这些患者在 1 年内无疾病进展的情况下对免疫疗法有积极反应。在免疫治疗的前四个周期中，CD8+T 记忆细胞和自然杀伤细胞最初增加，一年后恢复到基线水平。HNSCC 免疫治疗应答者的基线 CD8+T 细胞水平较低，但在免疫治疗后与健康受试者相似。这些发现表明，监测免疫谱的波动可能有助于确定 HNSCC 患者免疫治疗反应的生物标志物。
